Literature DB >> 6195956

Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis lesions.

Y Itoyama, H D Webster, E P Richardson, B D Trapp.   

Abstract

To investigate remyelination in multiple sclerosis lesions, we immunostained spinal cord sections from patients with multiple sclerosis and neurological normal (control) patients with antisera to P0 protein, a major constituent of peripheral nervous system myelin, and myelin basic protein, which is found in both central and peripheral nervous system myelin. In sections from five of the eight patients with no clinical or pathological evidence of neurological disease, P0 immunostaining was confined to peripheral myelin sheaths in dorsal and ventral roots. They were intensely stained, and peripheral--central nervous system transition zones were clearly demarcated. Sections from the other three control patients contained a few P0-stained sheaths in the central nervous system near root entry zones or among marginal glia near the dorsal sulcus. Spinal cord sections from six of the ten patients with multiple sclerosis contained clusters of myelin sheaths immunostained by P0 antiserum. These regenerating sheaths of peripheral nervous system origin were most numerous in large lesions and were commonly located in central areas or peripherally near root entry zones. The sheaths were observed frequently in areas of active demyelination and appeared morphologically normal even when surrounded by debris-filled macrophages. Near margins of small inactive plaques were a few basic protein--stained oligodendroglia extending processes to thin basic protein--stained sheaths.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195956     DOI: 10.1002/ana.410140313

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  38 in total

Review 1.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

2.  Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis.

Authors:  Roman Fischer; Tanja Padutsch; Valerie Bracchi-Ricard; Kayla L Murphy; George F Martinez; Niky Delguercio; Nicholas Elmer; Maksim Sendetski; Ricarda Diem; Ulrich L M Eisel; Richard J Smeyne; Roland E Kontermann; Klaus Pfizenmaier; John R Bethea
Journal:  Brain Behav Immun       Date:  2019-06-17       Impact factor: 7.217

Review 3.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

4.  A quantitative morphometric analysis of rat spinal cord remyelination following transplantation of allogenic Schwann cells.

Authors:  Karen L Lankford; Toshio Imaizumi; Osamu Honmou; Jeffery D Kocsis
Journal:  J Comp Neurol       Date:  2002-02-11       Impact factor: 3.215

Review 5.  Schwann cell invasion of the central nervous system of the myelin mutants.

Authors:  I D Duncan; R L Hoffman
Journal:  J Anat       Date:  1997-01       Impact factor: 2.610

Review 6.  Pluripotent stem cells for Schwann cell engineering.

Authors:  Ming-San Ma; Erik Boddeke; Sjef Copray
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

7.  Spinal cord multiple sclerosis lesions in Japanese patients: Schwann cell remyelination occurs in areas that lack glial fibrillary acidic protein (GFAP).

Authors:  Y Itoyama; A Ohnishi; J Tateishi; Y Kuroiwa; H D Webster
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  The interaction of Schwann cells with CNS axons in regions containing normal astrocytes.

Authors:  W F Blakemore; A J Crang; R Curtis
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

9.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

10.  A selective glial barrier at motor axon exit points prevents oligodendrocyte migration from the spinal cord.

Authors:  Sarah Kucenas; Wen-Der Wang; Ela W Knapik; Bruce Appel
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.